Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
Researchers at KTH Royal Institute of Technology developed a method to track the growth of the HIV virus by highlighting its essential molecules. This breakthrough could lead to the creation of new therapies that target these molecules to prevent viral growth.
A comprehensive study reveals SARS-CoV-2 viral-to-human protein interaction network, showing how the virus hijacks human proteins. Researchers identified 23 candidate drugs, including an FDA-approved beta-blocker that shows promise in inhibiting viral infection.
Few studies utilize high-throughput screening (HTS) and high-content screening (HCS) techniques in anti-obesity drug discovery due to a lack of original data or experimental design information. This limits the development of effective pharmaceutical treatments for obesity-related diseases.
Researchers from McGill University developed a medical adhesive inspired by flatworms that uses suction to absorb blood and promote blood coagulation. The adhesive can be removed without causing re-bleeding, making it a potential replacement for wound sutures or delivering drugs.
Two promising neurokinin B antagonists, fezolinetant and elinzanetant, are being developed for the treatment of vasomotor symptoms, including hot flashes. Larger studies are necessary to confirm their benefits and risks. Hormone therapy remains the most effective treatment option for menopausal women.
A large randomized clinical trial demonstrated Octagam 10% as an efficacious and well-tolerated treatment option for adult dermatomyositis patients. The study showed improved outcomes in patients with this rare disease, providing a much-needed treatment alternative.
Scientists at Northwestern University have identified a new gene that activates an aggressive subtype of small-cell lung cancer with no current effective treatment. Deleting this gene kills cancer cells in deadly subtype.
A Swedish cohort study found that direct oral anticoagulants (DOACs) were associated with a lower risk of kidney function decline or kidney failure compared to vitamin K antagonists (VKA). DOACs also showed a lower risk of acute kidney injury.
Researchers from the University of Cincinnati found that low levels of soluble amyloid-beta protein in the brain, rather than its buildup into plaques, are associated with cognitive decline and Alzheimer's disease. Patients with high levels of soluble amyloid-beta showed improved cognitive outcomes, contradicting previous theories.
A cross-sectional study of over 70,000 Asian Americans found significant variation in obesity prevalence among subgroups, with Filipino Americans having the highest rate at 28.7% and Chinese Americans the lowest at 13.2%. The study highlights the need for tailored strategies to address obesity disparities among Asian American populations.
The researchers will conduct multimodal imaging of 100 human vagus nerves using high-resolution technologies, providing unprecedented data on the vagus nerve's organization. This work aims to improve the safety and effectiveness of existing vagus nerve therapies, offering potential for novel neuromodulation therapies.
A new study found that fewer Asian, Black, and Hispanic patients qualify for anti-amyloid monoclonal antibody treatments, which may slow Alzheimer's progression. The treatment's effectiveness depends on the presence of amyloid plaques, with lower incidence in minorities.
Researchers at Universidad de Navarra identified a biomarker that predicts CAR T cell therapeutic capacity, which could improve treatment outcomes for patients. The study found that high CAR density in CAR T cells is associated with a worse clinical response in hematological tumors.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
The Leducq Foundation has awarded $7.5 million to UVA researchers, led by Mete Civelek, to investigate sex differences in atherosclerosis and $8 million to Coleen McNamara to advance immunotherapy for cardiovascular disease. These projects aim to improve understanding of heart disease and develop new treatments.
Researchers have discovered a drug candidate that can prevent lethal lung inflammation in mice by inhibiting PTP1B, a protein that accelerates neutrophil aging and reduces tissue damage. The treatment shows promise for treating acute respiratory distress syndrome (ARDS) and other inflammatory conditions.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Neflamapimod, a p38α kinase inhibitor, demonstrates reversible neurodegeneration in animal models and improves clinical endpoints associated with cholinergic neuronal function in patients with dementia with Lewy bodies. The findings support the initiation of a confirmatory Phase 2b clinical trial for neflamapimod.
A phase 3 clinical trial showed tofersen reduces SOD1 and neurofilament light protein levels, slowing down disease progression. Longer-term use may help stabilize muscle strength and control in people with genetic ALS.
Researchers have developed a flexible endoscopic imaging probe using a bendable graded index (GRIN) lens, enabling 3D microscopic imaging of tissue. The new technology could shorten biopsy waiting times to minutes and enable real-time monitoring of tissue changes.
A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.
Researchers from Temple University Health System developed a device that significantly reduces blood clot size in pulmonary arteries, leading to improved heart function and shorter treatment duration. The breakthrough is based on data collected in the NIH-sponsored RESCUE trial.
A randomized trial found that a 12-week online yoga program improved knee function in participants, but did not significantly reduce knee pain during walking. The study suggests that unsupervised online yoga programs can be feasible and improve physical function, but more research is needed to sustain the effectiveness.
A new study suggests that spironolactone, a medication for heart problems and high blood pressure, may also be effective in reducing alcohol drinking. The research found that increasing doses of spironolactone decreased alcohol consumption in mice and rats, as well as in humans with excessive alcohol drinking.
A new genomic test can predict a patient's risk of developing severe COVID-19, according to research from the University of Virginia Health System. The test, called CovGENE, analyzes genes expressed in a person's blood to determine if they may experience a severe disease course with increased risk of death.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
A team of scientists from Ural Federal University has developed a complex mathematical model to understand the dynamics of nanoparticles and viruses in cells. The model reveals how viruses cluster inside endosomes and interact with cellular proteins, shedding light on their behavior and replication mechanisms. This breakthrough can hel...
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A newly developed agonistic antibody targeting TREM2 reduced amyloid burden and alleviated cognitive decline in mice with Alzheimer's disease. The study suggests that increasing TREM2 activation could have therapeutic effects such as improved cognition.
A study by Case Western Reserve University has identified a promising path to developing therapies for esophageal tumors. The research team linked the TGFβ-pathway, a cell signaling mechanism, to tumor development and found that a protein-coding gene called HNF4α is a predictive biomarker of cancer.
Researchers from Tokyo Metropolitan University have developed a method to directly measure the strength of skeletal muscle myotubes by analyzing wrinkles formed on an elastic substrate when stimulated with electric pulses. This new technique is more sensitive than existing measures and has great potential for accelerating drug discover...
Researchers identified critical period plasticity in the amygdala that can be treated with therapeutic intervention at key developmental time points. Early pharmacological intervention was shown effective in reducing fear-learning in the mouse model.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers found that brief rapamycin exposure in early adulthood can prevent age-related decline and extend lifespan. The study used fruit flies and mice to test the effects of short-term drug administration, showing protection against intestinal pathology and increased health span.
A large cross-sectional study found that baseline plasma antigen levels are highly associated with both the severity of pulmonary illness and clinically important patient outcomes in hospitalized COVID-19 patients. Higher antigen levels were linked to increased risk of pulmonary worsening and delayed hospital discharge.
Researchers have developed a new treatment principle that combines DNA-based and protein-based vaccines to stimulate the immune system against both hepatitis B and D viruses. The treatment has been shown to protect cultured cells against HBV and HDV infection, producing high levels of neutralizing antibodies and T-cells.
A KAUST-led research team identified two drug treatments that boost the activity of molecules involved in cell adhesion, enhancing the ability of blood-forming stem cells to enter the bloodstream and produce new blood. This breakthrough could lead to improved bone marrow transplant success for leukemia patients.
The American College of Cardiology has published an expert consensus decision pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk reduction. The guidance provides recommendations for individuals at high-risk and those with familial hypercholesterolemia, ...
A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
A national survey of US psychiatrists found discrepancies between their perceptions of certain psychoactive drugs' safety and therapeutic value and how they are categorized under the Controlled Substances Act. Psychiatrists rated psilocybin as having low misuse potential and high therapeutic potential, but it is a Schedule I drug with ...
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
A proof-of-concept study developed three machine learning models to predict posttreatment recurrence in early-stage hepatocellular carcinoma patients. The models achieved high accuracy using imaging data alone, while combining clinical data did not significantly improve performance.
A Rutgers scientist has developed a highly sensitive DNA test that can detect Lyme disease in horses, a condition that can cause long-term complications. The test, called genomic hybrid capture assay, was tested on a sick horse and successfully identified the pathogen, allowing for early diagnosis and treatment.
The study found a 31% decline in sleep medication use between 2013 and 2018, with the strongest decrease in FDA-approved medications. Behavioral treatments for insomnia are increasingly encouraged due to their effectiveness and reduced risk of adverse outcomes.
Intravenous (IV) nutrition is being used by professional athletes as a regular routine, despite lack of scientific evidence supporting its effectiveness and potential risks. The 'food first' approach is crucial to avoid normalization of unproven treatments.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.
Researchers found that lidocaine injections reduced Psoriasis Area and Severity Index scores by 35-70% and maintained improvements for at least 24 weeks. The study suggests targeting sensory nerves as a potential therapeutic strategy for psoriasis treatment.
Researchers have discovered a functional link between STING signaling and immunometabolism, suggesting that PET imaging could measure the pharmacodynamic effects of STING-activating drugs. This approach may enable a whole-body analysis of immune activation in humans, guiding clinical development of anti-tumor therapy.
A study published in eLife identified three microRNAs that may impair healing in venous ulcers, a common type of chronic wound. The findings suggest that drugs targeting these microRNAs could help facilitate healing in patients, offering new approaches for treating this painful and slow-to-heal condition.
Researchers at Aston University have developed a new approach to tackle one of the underlying causes of asthma, not just its symptoms. The treatment, which targets the structural changes made by asthmatic airways, shows promising results in mice, reducing symptoms within two weeks and returning airways to near normal.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
Researchers at Okayama University discovered EPA's molecular target, which blocks purinergic chemical transmission and reduces pain perception. The study suggests EPA can be used as a therapeutic strategy for managing chronic pain with fewer side effects.
Researchers found that administering tisagenlecleucel at the higher end of the approved dose range significantly improves overall and event-free survival in young patients. The study suggests that using higher doses of CAR-T therapy can achieve more effective and long-term responses without increasing toxicity risk.
A clinical trial found that three smoking cessation treatments could also reduce alcohol consumption and found high rates of behavior change for both. Nicotine replacement therapy performed as well as prescription drugs in reducing alcohol intake.
The NCI-backed Molecular Targets Platform streamlines and catalyzes drug development by integrating pediatric cancer targets and pathways. This platform empowers researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer.